JP2017503472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503472A5 JP2017503472A5 JP2016515328A JP2016515328A JP2017503472A5 JP 2017503472 A5 JP2017503472 A5 JP 2017503472A5 JP 2016515328 A JP2016515328 A JP 2016515328A JP 2016515328 A JP2016515328 A JP 2016515328A JP 2017503472 A5 JP2017503472 A5 JP 2017503472A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- receptor
- cell
- icar
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 31
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 16
- 108020003175 receptors Proteins 0.000 claims 15
- 102000005962 receptors Human genes 0.000 claims 15
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 9
- 208000024908 graft versus host disease Diseases 0.000 claims 9
- 101710160107 Outer membrane protein A Proteins 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- -1 EGP-40 Proteins 0.000 claims 6
- 210000000265 leukocyte Anatomy 0.000 claims 6
- 230000004068 intracellular signaling Effects 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000003259 immunoinhibitory effect Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 101150030213 Lag3 gene Proteins 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100040120 Prominin-1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102100035721 Syndecan-1 Human genes 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 108091008042 inhibitory receptors Proteins 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361802118P | 2013-03-15 | 2013-03-15 | |
| US61/802,118 | 2013-03-15 | ||
| PCT/US2014/030671 WO2015142314A1 (en) | 2013-03-15 | 2014-03-17 | Compositions and methods for immunotherapy |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018174681A Division JP2018196396A (ja) | 2013-03-15 | 2018-09-19 | 免疫治療のための組成物および方法 |
| JP2021001277A Division JP2021052800A (ja) | 2013-03-15 | 2021-01-07 | 免疫治療のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503472A JP2017503472A (ja) | 2017-02-02 |
| JP2017503472A5 true JP2017503472A5 (enExample) | 2021-02-18 |
| JP6857028B2 JP6857028B2 (ja) | 2021-04-14 |
Family
ID=50513511
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515328A Active JP6857028B2 (ja) | 2013-03-15 | 2014-03-17 | 免疫治療のための組成物および方法 |
| JP2018174681A Withdrawn JP2018196396A (ja) | 2013-03-15 | 2018-09-19 | 免疫治療のための組成物および方法 |
| JP2020077143A Expired - Fee Related JP7076493B2 (ja) | 2013-03-15 | 2020-04-24 | 免疫治療のための組成物および方法 |
| JP2021001277A Withdrawn JP2021052800A (ja) | 2013-03-15 | 2021-01-07 | 免疫治療のための組成物および方法 |
| JP2022167507A Withdrawn JP2022186837A (ja) | 2013-03-15 | 2022-10-19 | 免疫治療のための組成物および方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018174681A Withdrawn JP2018196396A (ja) | 2013-03-15 | 2018-09-19 | 免疫治療のための組成物および方法 |
| JP2020077143A Expired - Fee Related JP7076493B2 (ja) | 2013-03-15 | 2020-04-24 | 免疫治療のための組成物および方法 |
| JP2021001277A Withdrawn JP2021052800A (ja) | 2013-03-15 | 2021-01-07 | 免疫治療のための組成物および方法 |
| JP2022167507A Withdrawn JP2022186837A (ja) | 2013-03-15 | 2022-10-19 | 免疫治療のための組成物および方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11267901B2 (enExample) |
| EP (2) | EP4098275A1 (enExample) |
| JP (5) | JP6857028B2 (enExample) |
| KR (3) | KR102466666B1 (enExample) |
| CN (1) | CN105246504A (enExample) |
| AU (2) | AU2014386824B2 (enExample) |
| BR (1) | BR112015023679A2 (enExample) |
| CA (1) | CA2904265C (enExample) |
| IL (2) | IL311390A (enExample) |
| MX (2) | MX386060B (enExample) |
| MY (1) | MY195733A (enExample) |
| NZ (1) | NZ712693A (enExample) |
| PH (1) | PH12015502271B1 (enExample) |
| RU (1) | RU2729118C2 (enExample) |
| SA (1) | SA515361180B1 (enExample) |
| SG (1) | SG11201507688VA (enExample) |
| WO (1) | WO2015142314A1 (enExample) |
| ZA (1) | ZA202306503B (enExample) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| AU2014386824B2 (en) * | 2013-03-15 | 2019-05-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| EP3789487A1 (en) * | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| EP3858379A1 (en) | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| CA2967222C (en) * | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| EP3227323B1 (en) | 2014-12-03 | 2020-08-05 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA2977106A1 (en) * | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| WO2016179319A1 (en) * | 2015-05-04 | 2016-11-10 | Cellerant Therapeutics, Inc. | Chimeric antigen receptors with ctla4 signal transduction domains |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201509413D0 (en) | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| US20180291080A1 (en) * | 2015-09-28 | 2018-10-11 | Trustees Of Dartmouth College | Chimeric antigen receptor, regulatory cells and methods of use |
| US12642852B1 (en) | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| CN122146606A (zh) | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| EP3377523A4 (en) * | 2015-11-19 | 2019-06-19 | The Regents of The University of California | CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF |
| CN109072194B (zh) | 2015-12-09 | 2022-12-27 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物及其使用方法 |
| EP3408671B1 (en) | 2016-01-25 | 2023-11-01 | F. Hoffmann-La Roche AG | Methods for assaying t-cell dependent bispecific antibodies |
| CN105567640A (zh) * | 2016-01-27 | 2016-05-11 | 苏州佰通生物科技有限公司 | 一种嵌合抗原受体脂肪干细胞及其制备方法 |
| AU2017240233B2 (en) * | 2016-03-31 | 2022-07-14 | University Of Southern California | A highly sensitive and specific luciferase based reporter assay for antigen detection |
| CN109414512A (zh) | 2016-04-22 | 2019-03-01 | 科济生物医药（上海）有限公司 | 用于细胞免疫疗法的组合物和方法 |
| EP3465203B1 (en) * | 2016-05-25 | 2026-03-18 | The Council of the Queensland Institute of Medical Research | Methods of immunotherapy |
| CN105950561A (zh) * | 2016-05-26 | 2016-09-21 | 江苏杰晟生物科技有限公司 | 一种靶向乳腺癌干细胞的双特异性嵌合抗原受体基因修饰的t淋巴细胞的制备方法及其产品 |
| WO2017210689A1 (en) * | 2016-06-03 | 2017-12-07 | Memorial Sloan-Kettering Cancer Center | Adoptive cell therapies as early treatment options |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| CA3034691A1 (en) | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| MX2019003462A (es) * | 2016-09-28 | 2019-08-16 | Gavish Galilee Bio Appl Ltd | Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer. |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CN107988164B (zh) | 2016-10-26 | 2020-07-07 | 阿思科力(苏州)生物科技有限公司 | 一种pd-1 car nk-92细胞及其制备方法与应用 |
| EP3315511A1 (en) * | 2016-10-29 | 2018-05-02 | Miltenyi Biotec GmbH | Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
| JP7078937B2 (ja) * | 2016-12-21 | 2022-06-01 | ダンマークス テクニスク ユニバーシテット | 免疫細胞を操作するための抗原提示足場 |
| WO2018124766A2 (ko) * | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| AU2018231190B2 (en) * | 2017-03-08 | 2023-05-25 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| CN109097402B (zh) * | 2017-03-31 | 2021-09-07 | 国健呈诺生物科技(北京)有限公司 | 一种重组载体CAR-CD244-antiCD19的制备方法 |
| JP2020517259A (ja) * | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| GB201707779D0 (en) * | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
| EP3631468A1 (en) | 2017-06-02 | 2020-04-08 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
| PL3688155T3 (pl) | 2017-09-28 | 2023-09-11 | Immpact-Bio Ltd. | Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar) |
| CN109593721B (zh) * | 2017-09-30 | 2022-11-01 | 亘喜生物科技（上海）有限公司 | 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| KR102774451B1 (ko) | 2017-11-14 | 2025-02-28 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| WO2019111249A1 (en) * | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
| US12139522B2 (en) | 2017-12-05 | 2024-11-12 | The Medical Research Infrastructure And Heal Serviced Fund Of The Tel Aviv Medecal Center | T-cells comprising two different chimeric antigen receptors and uses thereof |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| IL326873A (en) * | 2017-12-29 | 2026-04-01 | Memorial Sloan Kettering Cancer Center | Enhanced chimeric antigen receptors and uses thereof |
| CN111867619A (zh) | 2018-01-03 | 2020-10-30 | 曲生物制品公司 | 过继性细胞治疗的先天寻靶 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| CN109321530B (zh) * | 2018-02-12 | 2021-03-12 | 华东师范大学 | 一种安全型嵌合抗原受体t细胞及其用途 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3773588A4 (en) * | 2018-04-09 | 2022-01-19 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASES |
| CN110526976A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向psma的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN110526984A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向psma的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| WO2019242632A1 (en) * | 2018-06-19 | 2019-12-26 | 1§1Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
| TW202016144A (zh) * | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| BR112021006100A2 (pt) | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| EP3856769A4 (en) * | 2018-09-28 | 2022-08-17 | Memorial Sloan Kettering Cancer Center | IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12624086B2 (en) | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12466892B2 (en) | 2018-11-08 | 2025-11-11 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| CN109517799B (zh) * | 2018-11-30 | 2022-07-26 | 北京美康基免生物科技有限公司 | 一种基于cd19和cd22的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
| ES3051182T3 (en) | 2019-01-23 | 2025-12-26 | Miltenyi Biotec Bv & Co Kg | A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| CN110592014A (zh) * | 2019-08-14 | 2019-12-20 | 广东美赛尔细胞生物科技有限公司 | 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法 |
| EP4017510A4 (en) * | 2019-08-20 | 2023-11-22 | Senti Biosciences, Inc. | CHIMERIC INHIBITOR RECEPTOR |
| WO2021041920A1 (en) * | 2019-08-28 | 2021-03-04 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2021044213A2 (en) * | 2019-09-05 | 2021-03-11 | Migal-galilee Research Institute Ltd. | Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells |
| US20220372092A1 (en) * | 2019-10-18 | 2022-11-24 | Board Of Regents, The University Of Texas System | Hla-restricted vcx/y peptides and t cell receptors and use thereof |
| AU2020397170A1 (en) * | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
| WO2021119489A1 (en) | 2019-12-11 | 2021-06-17 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| CN115066249A (zh) | 2020-02-04 | 2022-09-16 | 美天施生物科技有限两合公司 | 表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞 |
| WO2021168317A1 (en) * | 2020-02-20 | 2021-08-26 | Senti Biosciences, Inc. | Inhibitory chimeric receptor architectures |
| CN111249314B (zh) * | 2020-03-03 | 2022-03-29 | 深圳未知君生物科技有限公司 | 人体共生菌群在提高肿瘤免疫治疗应答中的作用 |
| CN115916250A (zh) * | 2020-05-20 | 2023-04-04 | 美天施生物科技有限两合公司 | 用于治疗表达cd90和cd326的癌症的组合物和方法 |
| US12286465B2 (en) | 2020-05-28 | 2025-04-29 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains |
| WO2022007784A1 (en) * | 2020-07-06 | 2022-01-13 | Nanjing Legend Biotech Co., Ltd. | Methods of reducing graft rejection of allogeneic cell therapy |
| US20230272039A1 (en) | 2020-07-16 | 2023-08-31 | Umoja Biopharma, Inc. | Gated adapter targeting receptor |
| US20230257441A1 (en) * | 2020-08-13 | 2023-08-17 | A2 Biotherapeutics, Inc. | Compositions and methods for treating cancers |
| WO2022037323A1 (zh) * | 2020-08-19 | 2022-02-24 | 上海易慕峰生物科技有限公司 | 人源化抗体、嵌合抗原受体、核酸、载体、细胞及应用 |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| US11433100B2 (en) | 2020-08-20 | 2022-09-06 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| EP4058474B1 (en) | 2020-08-20 | 2024-05-08 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| EP4097486A4 (en) | 2020-08-20 | 2023-09-06 | A2 Biotherapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER |
| US20220090015A1 (en) | 2020-09-21 | 2022-03-24 | A2 Biotherapeutics, Inc. | Engineered immune cells with multiplex and localized activity |
| WO2022096664A1 (en) | 2020-11-09 | 2022-05-12 | Miltenyi Biotec B.V. & Co. KG | Methods and compositions for eliminating engineered immune cells |
| CN116723861A (zh) | 2020-12-02 | 2023-09-08 | 上海复宏汉霖生物技术股份有限公司 | 抗GARP/TGFβ抗体及使用方法 |
| CN114569708B (zh) * | 2020-12-02 | 2023-07-04 | 四川大学华西医院 | Nkg2d car-免疫细胞在抗衰老中应用 |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4255454A4 (en) * | 2020-12-07 | 2025-01-08 | The Johns Hopkins University | NATURAL KILLER CELL ENGINEERING METHODS TO ENHANCE TUMOR TARGETING |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| US20240082306A1 (en) * | 2021-02-03 | 2024-03-14 | Bioheng Therapeutics Limited | Novel chimeric antigen receptor and use thereof |
| IL304857A (en) | 2021-02-16 | 2023-10-01 | A2 Biotherapeutics Inc | Preparations and methods for treating HER2 POSITIVE cancer |
| CA3213040A1 (en) * | 2021-03-22 | 2022-09-29 | Michel Sadelain | Cd38 chimeric co-stimulating receptor and uses thereof |
| US20240390497A1 (en) * | 2021-09-15 | 2024-11-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions of chimeric antigen receptor (car) signaling molecules and uses thereof |
| WO2023057285A1 (en) | 2021-10-06 | 2023-04-13 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| CN118488965A (zh) | 2021-12-17 | 2024-08-13 | 上海复宏汉霖生物技术股份有限公司 | 抗ox40抗体、多特异性抗体及其使用方法 |
| AU2022411573A1 (en) | 2021-12-17 | 2024-06-27 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies and methods of use |
| KR20240163119A (ko) | 2022-03-25 | 2024-11-18 | 상하이 헨리우스 바이오테크, 인크. | 항-msln 항체 및 사용 방법 |
| WO2024078995A1 (en) | 2022-10-15 | 2024-04-18 | Miltenyi Biotec B.V. & Co. KG | Transduction of gammadelta t cells with pseudotyped retroviral vectors |
| CN116785458A (zh) * | 2023-02-14 | 2023-09-22 | 青岛大学 | 半滑舌鳎抗病蛋白shp-1基因的应用 |
| CN116376844B (zh) * | 2023-05-31 | 2023-08-11 | 四川大学华西医院 | 包含shp2 sh2结构域的靶向her2阳性肿瘤的car-t及制备方法和应用 |
| CN119119191B (zh) * | 2024-09-13 | 2025-04-01 | 渤海大学 | 一种海参肠多肽及其在制备胃部疾病药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2008038587A1 (fr) | 2006-09-25 | 2008-04-03 | National University Corporation Nagoya University | Lignée cellulaire du lymphome b malin modifié négativement par cd20 |
| PT2126054T (pt) * | 2007-01-31 | 2016-10-12 | Yeda Res & Dev | Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias |
| US8389282B2 (en) * | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| MX2014001222A (es) * | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| SG11201507026WA (en) | 2013-02-06 | 2015-10-29 | Anthrogenesis Corp | Modified t lymphocytes having improved specificity |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| AU2014386824B2 (en) * | 2013-03-15 | 2019-05-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| ES2769574T3 (es) * | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
-
2014
- 2014-03-17 AU AU2014386824A patent/AU2014386824B2/en active Active
- 2014-03-17 NZ NZ712693A patent/NZ712693A/en unknown
- 2014-03-17 EP EP21213658.4A patent/EP4098275A1/en active Pending
- 2014-03-17 WO PCT/US2014/030671 patent/WO2015142314A1/en not_active Ceased
- 2014-03-17 JP JP2016515328A patent/JP6857028B2/ja active Active
- 2014-03-17 EP EP14718296.8A patent/EP2968492B1/en active Active
- 2014-03-17 SG SG11201507688VA patent/SG11201507688VA/en unknown
- 2014-03-17 BR BR112015023679A patent/BR112015023679A2/pt not_active Application Discontinuation
- 2014-03-17 MY MYPI2015002377A patent/MY195733A/en unknown
- 2014-03-17 MX MX2015013104A patent/MX386060B/es unknown
- 2014-03-17 KR KR1020227002101A patent/KR102466666B1/ko active Active
- 2014-03-17 KR KR1020157029137A patent/KR20150128997A/ko not_active Ceased
- 2014-03-17 IL IL311390A patent/IL311390A/en unknown
- 2014-03-17 RU RU2015143207A patent/RU2729118C2/ru active
- 2014-03-17 CA CA2904265A patent/CA2904265C/en active Active
- 2014-03-17 IL IL300508A patent/IL300508A/en unknown
- 2014-03-17 CN CN201480027699.9A patent/CN105246504A/zh active Pending
- 2014-03-17 KR KR1020227039192A patent/KR20220156663A/ko active Pending
-
2015
- 2015-09-11 US US14/851,983 patent/US11267901B2/en active Active
- 2015-09-15 PH PH12015502271A patent/PH12015502271B1/en unknown
- 2015-09-15 MX MX2019014008A patent/MX2019014008A/es unknown
- 2015-09-15 SA SA515361180A patent/SA515361180B1/ar unknown
-
2018
- 2018-09-19 JP JP2018174681A patent/JP2018196396A/ja not_active Withdrawn
-
2019
- 2019-08-06 AU AU2019213338A patent/AU2019213338A1/en not_active Abandoned
-
2020
- 2020-04-24 JP JP2020077143A patent/JP7076493B2/ja not_active Expired - Fee Related
-
2021
- 2021-01-07 JP JP2021001277A patent/JP2021052800A/ja not_active Withdrawn
-
2022
- 2022-01-24 US US17/583,117 patent/US12275802B2/en active Active
- 2022-10-19 JP JP2022167507A patent/JP2022186837A/ja not_active Withdrawn
-
2023
- 2023-06-23 ZA ZA2023/06503A patent/ZA202306503B/en unknown
-
2025
- 2025-03-11 US US19/076,055 patent/US20250270347A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020114255A5 (enExample) | ||
| RU2015143207A (ru) | Композиции и способы иммунотерапии | |
| IL276554B1 (en) | Non-hla restricted t cell receptors and uses thereof | |
| JP2021513347A5 (enExample) | ||
| JP2015535689A5 (enExample) | ||
| Whiteside et al. | Emerging opportunities and challenges in cancer immunotherapy | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| JP2016513458A5 (enExample) | ||
| JP2017531687A5 (enExample) | ||
| Bollino et al. | Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy | |
| RU2015116901A (ru) | Композиции и способы для имуннотерапии | |
| Shi et al. | Improving the efficacy and safety of engineered T cell therapy for cancer | |
| ZA201901557B (en) | Bi specific anti¿muc16¿cd3 antibodies and anti¿muc16 drug conjugates | |
| RU2015140811A (ru) | Композиции и способы иммунотерапии | |
| JP2021505604A5 (enExample) | ||
| Bachireddy et al. | Haematological malignancies: at the forefront of immunotherapeutic innovation | |
| JP2016508728A5 (enExample) | ||
| Curiel | Immunotherapy: a useful strategy to help combat multidrug resistance | |
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| RU2019136640A (ru) | Композиции с улучшенными т-клетками и способы | |
| Riether et al. | From “magic bullets” to specific cancer immunotherapy | |
| Sha et al. | Chimaeric antigen receptor T-cell therapy for tumour immunotherapy | |
| Kato et al. | Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies | |
| WO2017177217A3 (en) | Chimeric receptors and uses thereof in immune therapy |